1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Drugs In Development, 2022, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Burkholderia pseudomallei Infections (Melioidosis) - Overview
- Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
- Aceragen Inc
- AN2 Therapeutics Inc
- Bugworks Research Inc
- Entasis Therapeutics Holdings Inc
- Soligenix Inc
- Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles
- Product Description
- Mechanism Of Action
- History of Events
- BWC-0977 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epetraborole - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fusidic acid - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- melioidosis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- POLB-003 - Drug Profile
- Product Description
- Mechanism Of Action
- SGX-943 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Infectious Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
- Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
- Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
- Featured News & Press Releases
- Jun 15, 2022: Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis
- May 18, 2022: Poolbeg Pharma : European Melioidosis Congress
- Jan 05, 2022: Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for development of ACG-701 as medical countermeasure against melioidosis
- Apr 26, 2021: Bugworks secures funding from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
- Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference
- May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis
- Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
- Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Aceragen Inc, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by AN2 Therapeutics Inc, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bugworks Research Inc, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Entasis Therapeutics Holdings Inc, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, 2022
- Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, 2022
- Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aceragen Inc
- AN2 Therapeutics Inc
- Bugworks Research Inc
- Entasis Therapeutics Holdings Inc
- Soligenix Inc
